All patients had persistent tumor responses, with 2 complete responses and 1 case of stable disease.

The IL-23 inhibitor lowered the risk of uveitis more than TNF-α inhibitors in patients with moderate to severe psoriasis.

Announced on September 18, 2024, the approval of benralizumab for adults with EGPA, which is based on the MANDARA trial, marks the second FDA approval for EGPA.

The FDA has approved the Eversense 365, the world’s first 1-year continuous glucose monitor, with US availability expected in late 2024.

A report shows only 24%, 56%, and 62% of patients meet the criteria PSIL-AT for depression according to low-bound, mid-range, and upper-bound estimates, respectively.

At Maui Derm NP+PA Fall 2024, bimekizumab data demonstrates a consistent safety profile in moderate to severe plaque psoriasis over 4 years, with decreasing event rates over time.

Types of occupation did not significantly affect response to treatment.

This interview featured a literature review discussion about non-FDA approved advancements in dermatology, including oral roflumilast for psoriasis, metformin for acne, and minoxidil for nails.

Moser reviews ongoing unmet needs in PBC and how the addition of 2 new second-line treatment options has changed the treatment landscape.

In this interview segment, Chovatiya highlights HS therapies such as IL-17 inhibitors and JAK inhibitors, as well as unmet needs of patients.

A new study revealed those who consume a moderate amount of coffee or caffeine had a 48.1% and 40.7% reduced risk for developing cardiometabolic multimorbidity.

This interview with Chovatiya highlights promising therapies in the dermatology space for the treatment of patients with the skin condition HS.

Mathew emphasizes the importance of routine liver cancer screening in patients with advanced liver disease and the need to overcome insurance barriers for HCC panel testing.

Gildeuretinol showed a clinically meaningful reduction in geographic atrophy lesion growth and a favorable safety profile at 24 months in the Phase 3 SAGA trial.

Leo Pharma announced the availability of a single-dose autoinjector of tralokinumab for moderate-to-severe atopic dermatitis, approved by the FDA in June 2024.

Iordache emphasizes the importance of a multidisciplinary approach to liver disease care in pregnant patients and the need for patient education.

Here's what to expect from the new pulmonology research quarterly newsletter powered by the American Lung Association Research Institute.

In this Maui Derm fall conference session, Callender highlights approaches to pigmentation issues such as vitiligo, melasma, and other disorders.

People living with HP generally experience a profound lack of knowledge about their disease, driving poorer health-related quality of life. A study sought to create educational resources to curb this effect.

Better known as brittle bone disease, osteogenesis imperfecta can cause severe respiratory distress at birth and longterm effect to respiratory function. Morello shares his team's research into the cause of this effect.

Patients also experienced a substantial decrease in systolic blood pressure and diastolic blood pressure.

Counting down the most impactful news at major medical meetings, it’s the HCPLive Five! This episode focuses on 5 key updates from the European Society of Cardiology (ESC) Congress 2024.

These poster data highlight that atopic dermatitis treatment may be suboptimal in certain patients, demonstrating the necessity of additional effective therapy options.

Lindsay S. Ackerman, MD, FAAD, and Jonathan Silverberg, MD, PhD, MPH, provide clinical insights on best practices for monitoring patients with atopic dermatitis who are receiving JAK inhibitors.

Experts on atopic dermatitis compare the safety profile of JAK inhibitors with traditional and more advanced treatments currently available for patients.